Is Synjardy (empagliflozin/metformin) safe and appropriate for an adult with type 2 diabetes and non‑alcoholic fatty liver disease (mild‑to‑moderate) who has adequate renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Synjardy and Fatty Liver Disease

Synjardy (empagliflozin/metformin) is safe and appropriate for adults with type 2 diabetes and mild-to-moderate non-alcoholic fatty liver disease when renal function is adequate (eGFR ≥30 mL/min/1.73 m²), and this combination actively improves liver steatosis beyond glucose control alone. 1

Safety Profile in NAFLD/MASLD

Both components of Synjardy are explicitly endorsed for use in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD):

  • Metformin can be used in adults with compensated cirrhosis and preserved renal function, according to the 2024 EASL-EASD-EASO guidelines, though it should not be used in decompensated cirrhosis due to lactic acidosis risk. 1

  • SGLT2 inhibitors (empagliflozin) can be used in adults with Child-Pugh class A and B cirrhosis, demonstrating safety even in more advanced liver disease than mild-to-moderate NAFLD. 1

  • For patients with only mild-to-moderate fatty liver disease (no cirrhosis), both medications carry no hepatic contraindications and are considered first-line therapy. 1, 2

Therapeutic Benefits for Liver Disease

The empagliflozin component provides direct benefits for fatty liver disease beyond metformin alone:

  • Empagliflozin added to metformin significantly reduced liver steatosis grade, CAP scores (293.5 to 267.0), and ALT levels (68.5 to 45.0) after 6 months in a 2023 study of T2DM patients with NAFLD. 3

  • The combination therapy improved steatosis grades by both ultrasound and fibroscan modalities more effectively than metformin monotherapy in multiple 2024 trials. 4, 5

  • Weight reduction with empagliflozin (mean -5.78 kg vs +0.93 kg with comparators) contributes to liver fat reduction, as weight loss is a key mechanism for NAFLD improvement. 4

Renal Function Requirements

Metformin dosing must be adjusted based on eGFR:

  • Standard dosing is safe for eGFR ≥45 mL/min/1.73 m² without dose adjustment. 6, 2, 7

  • Reduce metformin to maximum 1,000 mg/day for eGFR 30-44 mL/min/1.73 m², with monitoring every 3-6 months. 6, 2, 7

  • Metformin is contraindicated when eGFR <30 mL/min/1.73 m² due to lactic acidosis risk. 6, 2

Empagliflozin can be initiated when eGFR ≥20 mL/min/1.73 m² for cardiorenal benefits, though glucose-lowering effects diminish below 45 mL/min/1.73 m². 2, 8

Clinical Implementation Algorithm

For a patient with T2DM, mild-to-moderate NAFLD, and adequate renal function:

  1. Verify eGFR ≥30 mL/min/1.73 m² before prescribing Synjardy. 6, 2

  2. Start with standard dosing (empagliflozin 5-10 mg/metformin 500-1000 mg twice daily) if eGFR ≥45 mL/min/1.73 m². 9

  3. If eGFR is 30-44 mL/min/1.73 m², limit total metformin to 1,000 mg/day maximum and consider using empagliflozin 10 mg once daily with metformin 500 mg twice daily. 2, 7

  4. Monitor eGFR every 3-6 months once eGFR falls below 60 mL/min/1.73 m². 2, 7

  5. Temporarily discontinue metformin during acute illness, contrast procedures, or hospitalization. 7

Important Caveats

Volume depletion monitoring is essential as empagliflozin has diuretic effects, particularly in patients on other diuretics or antihypertensives. 8

The combination provides cardiovascular and renal benefits independent of glucose lowering, making it appropriate even if HbA1c targets are already achieved. 10, 2, 8

Liver enzyme monitoring is not required specifically for medication safety, though ALT/AST trends can help assess therapeutic response to treatment. 3, 4, 5

The presence of NAFLD is not a contraindication but rather an additional indication for this combination, as both components are safe in liver disease and empagliflozin actively improves hepatic steatosis. 1, 3, 5

References

Guideline

Metformin Use in Patients with eGFR 36

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initiating Jardiance in Type 2 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Is it appropriate to restart metformin in a 70‑year‑old female with type 2 diabetes mellitus, hemoglobin A1c 7.4%, currently on empagliflozin (Jardiance) 25 mg daily and semaglutide causing constipation, and what dosing regimen should be used?
What should be added next to empagliflozin (Jardiance) and metformin in a 74‑year‑old man with type 2 diabetes who declines a GLP‑1 receptor agonist (semaglutide, Ozempic) and has hyperglycemia (elevated fasting glucose and hemoglobin A1c)?
What adjustments should be made to the treatment plan for a patient with hyperglycemia, currently taking Jardiance (Empagliflozin) 25mg and Janumet (Sitagliptin/Metformin) 50-1000mg?
What is the recommended A1C target for a 65-year-old male with concurrent gout, hypertension (HTN), taking metformin (biguanide) 500 BID, Ozempic (semaglutide), and Jardiance (empagliflozin)?
In a 47-year-old male with hemoglobin A1c of 10.5% who is taking metformin 1 gram twice daily and Jardiance (empagliflozin) 25 mg daily and experiences morning nausea after metformin, how should his therapy be adjusted?
What is the recommended medical management for an adult patient who is neurologically intact with a 2 mm acute subdural hematoma on the right tentorial fold and no coagulopathy or anticoagulant use?
In a hypertensive patient, what is renal function and how should it be evaluated, monitored, and managed?
How should I manage elevated liver function tests in a patient taking isotretinoin (Accutane)?
What is the optimal documentation format for a cryotherapy treatment of a wart, including patient age, gender, immunosuppression, diabetes mellitus, prior wart therapies, lesion details, consent, technique, immediate response, and follow‑up plan?
Is doxepin safe as a sleep aid for elderly patients with cardiac disease (e.g., coronary artery disease, heart failure, arrhythmias) who are taking beta‑blockers, ACE inhibitors, diuretics, anticoagulants, or anti‑arrhythmic agents?
What is the recommended stepwise pharmacologic management for an adult with shoulder pain, including NSAIDs, topical NSAIDs, acetaminophen, oral corticosteroids, opioids, muscle relaxants, and neuropathic agents, and how should therapy be modified for contraindications such as peptic ulcer disease, severe renal impairment, uncontrolled hypertension, or cardiovascular risk?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.